Non-ischemic cardiomyopathy patients derive superior mortality benefit from cardiac resynchronization therapy.
BACKGROUND
Cardiac Resynchronization Therapy (CRT) is indicated for the treatment of advanced heart failure with severe systolic dysfunction and intraventricular conduction delay. Patient selection for this technology is vital, though it remains unclear which patients benefit most from CRT. We tested the hypothesis that patients with non-ischemic cardiomyopathy have a superior mortality benefit from CRT than ischemic cardiomyopathy patients.


METHODS
We evaluated 95 CRT patients to determine which factors predict mortality.


RESULTS
Patients with non-ischemic cardiomyopathy had a significantly better prognosis than patients with ischemic cardiomyopathy.


CONCLUSIONS
Larger prospective studies can substantiate this finding and better delineate which patients benefit most from CRT.
Rosman
Jonathan
J
Beth Israel Medical Center, University Hospital and Manhattan Campus for the Albert Einstein College of Medicine New York, New York, USA. jrosman@chpnet.org
Dhillon
Sandeep
S
Mayer
Alexander
A
Hanon
Sam
S
Paul
Schweitzer
S